Stocktoria
Caribou Biosciences, Inc. CRBU
Caribou Biosciences, Inc. (CRBU) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $11.2M at a -1327.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.683 |
| Retained earnings / assets | -3.402 |
| EBIT / assets | -0.846 |
| Equity / liabilities | 2.297 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| TSHA | Taysha Gene Therapies, Inc. | 4/9 | -0.53 | — | — |
| CRIS | CURIS INC | 2/9 | — | — | -13.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
FAQ
Is CRBU financially healthy?
Caribou Biosciences, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CRBU pay a dividend?
No, Caribou Biosciences, Inc. does not currently pay a dividend.
How profitable is CRBU?
In FY2025, Caribou Biosciences, Inc. had a net margin of -1327.4% and a return on equity of -121.2%.
What is the analyst price target for CRBU?
The average Wall-Street price target for Caribou Biosciences, Inc. is $12.00, about 605.9% above the recent price, from 7 analysts (consensus: strong buy).
Is CRBU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Caribou Biosciences, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.